A Phase II, Open Label, Single Arm, Multicenter Study of INC280 Administered Orally in Adults With Advanced Hepatocellular Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2019
At a glance
- Drugs Capmatinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 10 Apr 2019 Planned End Date changed from 28 Mar 2019 to 27 Jan 2020.
- 10 Apr 2019 Planned primary completion date changed from 28 Mar 2019 to 27 Jan 2020.
- 31 Aug 2018 Biomarkers information updated